Delenex completes Second Tranche of Series A Financing RoundApril 2012. At the end of February 2012, Delenex Therapeutics AG, a Swiss biotech company developing therapeutic antibody fragments for diseases with high unmet need, successfully completed a Second Tranche of the series A financing round worth CHF 16.7 million, bringing the total A round investment to CHF 30.2 million. April 2012. At the end of February 2012, Delenex Therapeutics AG, a Swiss biotech company developing therapeutic antibody fragments for diseases with high unmet need, successfully completed a Second Tranche of the series A financing round worth CHF 16.7 million, bringing the total A round investment to CHF 30.2 million. Delenex Therapeutics AG was advised on this transaction by Homburger. The Homburger team was led by partner Dieter Gericke and included associate Emanuel Dettwiler (both Corporate | M&A).  |
Deals & Cases
© 2013 Homburger AG
